Given the strong immune regulatory activity endorsed by FLIP expression, we assessed the ability of c-FLIP-infected CD14+ monocytes to control the graft vs host disease (GvHD) progression in a setting of xenogeneic transplantation. The gene discussed is CFLAR; the disease is glycogen storage disease VI.